IDEXX Laboratories is expected to report Q3 2026 revenue of $1.19 billion and EPS of $3.71, with its current stock price of $575.98 trading well below the average analyst price target of $717.92.
Investors are primarily focused on the organic revenue growth of the Companion Animal Group (CAG) Diagnostics segment, which is projected to rise 7.9% year-over-year.
This growth is underpinned by the continued expansion of the premium instrument installed base, particularly the AI-powered inVue Dx analyzer, and high adoption of new Cancer Dx testing panels. The company’s recurring revenue model and international commercial scaling are expected to drive margin expansion despite broader macroeconomic uncertainty.